Although controversial data has been published recently [46], there is vast preclinical data showing that PI3K signaling enhances metastatic potential and that PI3K pathway inhibition reduces metastatic dissemination of colorectal cancer cells carrying a mutated WNT pathway, which supports our findings [47-52]. This evidence concerns the gene PIK3CA and colorectal cancer.